Климодиен

Quick links to important sections

Климодиен

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Климодиен

What is Climodiene (Климодиен)?

Property Description
Active Ingredients Estradiol Valerate and Dienogest
Form Film-Coated Tablet
Pharmacological Class Estrogen-Progestin Combination Hormonal Agent
Common Use Hormone Replacement Therapy (HRT) for menopausal symptoms
Origin Synthetic/Derived

Climodiene is a medicinal product classified as a Hormone Replacement Therapy (HRT) agent, specifically an Estrogen-Progestin Combination Hormonal Agent. It is designed for systemic use to compensate for the natural hormone decline that occurs after menopause. This type of treatment is clinically recognized for its effectiveness in helping women restore hormonal balance and minimize the general discomforts and symptoms of estrogen deficiency.

Identity and Composition

Climodiene is a fixed-dose combination product that contains two distinct active ingredients: Estradiol Valerate (an estrogen component) and Dienogest (a progestin component). This type of combination is recognized as effective for managing vasomotor symptoms related to menopause.

The medicine is supplied as oral, film-coated tablets, and is administered via a continuous combined regimen. This approach means the user takes both the estrogen and progestin components daily in the same fixed dose. This continuous administration is a distinguishing feature from older, cyclical HRT products. The progestin component, Dienogest, plays a critical protective role; progestins are necessary in combination HRT to prevent the excessive thickening of the uterine lining caused by unopposed estrogen. This makes Climodiene a suitable option for postmenopausal women with an intact uterus.

What side effects are possible with Климодиен?

Possible side effects and safety information

The safety profile of Climodiene, a continuous combined Hormone Replacement Therapy (HRT), is established through its official regulatory documentation, presenting documented adverse events grouped by frequency and affected body system. These characteristics reflect general safety patterns associated with combination HRT.

Common Adverse Reactions

Side effects classified as common in official documents often involve the reproductive system, nervous system, and breasts. These include headache, breast pain or discomfort, nausea, and irregular uterine or vaginal bleeding patterns, such as spotting or breakthrough bleeding.


Serious Adverse Reactions and Major Safety Patterns

Like all systemic HRT products, Climodiene is associated with officially documented serious adverse reactions concerning vascular and neoplastic risks. These are classified as major, identified risks:

  • Vascular Disorders: Documented increased risk of Venous Thromboembolism (VTE), which includes Deep Vein Thrombosis (DVT) and Pulmonary Embolism, especially during the first year of use. Arterial events, such as Ischemic Stroke and Coronary Artery Disease (CAD), are also noted risks.
  • Neoplasms: The use of combined estrogen-progestin therapy is associated with documented elevated risks of Breast Cancer, Ovarian Cancer, and Endometrial Carcinoma.

System-Specific Effects and Safety Constraints

Official labeling notes additional systemic adverse effects, including changes in weight, episodes of depression, and the appearance of Chloasma (skin pigmentation). The medicine is formally contraindicated in individuals with severe hepatic impairment or with a history of liver tumours, reflecting a key safety constraint. Furthermore, irregular uterine bleeding and spotting are frequently documented to occur during the first months of treatment and may resolve over time.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for an acute overdosage of Climodiene (Estradiol Valerate and Dienogest) defines a limited set of documented clinical manifestations and required emergency actions. Overexposure may result in primarily gastrointestinal and reproductive symptoms.

Documented Overdose Manifestations and Risk Profile

Acute overdosage is documented to present with specific clinical signs listed in regulatory labeling. These include nausea and vomiting, as well as the expected gynecological response of withdrawal bleeding in females.

It is explicitly stated in official prescribing information that no reports of serious ill effects have been documented following acute overdosage of this hormonal combination. This includes scenarios involving inadvertent ingestion by children. The acute risk profile is thus officially documented as low in severity.

Emergency Actions and Management

Regulatory authorities mandate specific, immediate actions in the event of a suspected overdose. It is required to seek immediate medical attention and contact the Poison Help line for expert guidance regarding the exposure. This action is necessary for proper assessment and management, regardless of the apparent low documented severity.

It is documented that no specific antidote is known that can pharmacologically reverse the effects of the active components. Consequently, the management of acute overdose is based entirely on providing symptomatic and supportive treatment appropriate to the patient’s clinical state, ensuring that any necessary observation or supportive care can be initiated by healthcare professionals as required by protocol.

Therapeutic Uses of Климодиен

What Climodiene Treats: Main Uses and Benefits

Climodiene is a Hormone Replacement Therapy (HRT) specifically used to manage the symptoms caused by estrogen deficiency in postmenopausal women with an intact uterus. Its therapeutic benefit is centered on providing supportive relief across major symptom domains that create noticeable physiological strain and interfere with daily functioning. The core therapeutic area for this continuous combined therapy is hormone replacement therapy for estrogen deficiency symptoms in women who are at least one year postmenopausal and who still have their uterus.


Key Symptom Management and Therapeutic Support

The medication is commonly applied to help ease moderate to severe vasomotor symptoms, which include bothersome hot flushes and soaking night sweats. Symptomatic management in this domain supports a benefit by addressing the underlying systemic imbalance, which generally may contribute to improved sleep quality and assists with maintaining functional stability. The treatment is also relevant for managing related psychoemotional distress, covering symptom clusters like irritability, mood swings, and sleep disturbances, and provides support for symptoms of urogenital atrophy, such as vaginal dryness and discomfort during painful intercourse.

“The intent of this supportive therapy is generally to help ease the overall symptom burden, contributing to improved comfort during symptomatic periods.”

A relevant long-term therapeutic use is for managing the risk of postmenopausal osteoporosis, where the treatment is applied to address the systemic imbalance that may lead to bone loss, thereby contributing to easing the overall symptom load by supporting future skeletal health.


Quick Fact: Supports management of hot flushes, night sweats, and osteoporosis risk.

Regulatory References

  1. Public Assessment Report on Climodien

Eligibility and Restrictions for Use

Official Eligibility Profile: Who Can and Cannot Use Климодиен?

The use of this medicine is strictly defined by regulatory documents, specifying the eligible population and absolute exclusions.

Population Category Eligibility Status
Eligible Target Group Postmenopausal women seeking hormone replacement therapy for estrogen deficiency symptoms, typically those who are more than one year post-menopause.
Geriatric Use Restricted. Experience is limited in women older than 65 years.

Absolute Contraindications (Must NOT Use)

The medicine is contraindicated and must not be used by individuals with the following official exclusions:

  • Malignancies: Current or suspected breast cancer or any other estrogen-sensitive malignant tumors (e.g., endometrial cancer).
  • Vascular/Thrombotic Risk: Current or previous venous thromboembolism (DVT, PE), arterial thromboembolic disease (MI, stroke), or known thrombophilic disorders (e.g., protein C, S deficiency).
  • Organ/Physiological States: Current or history of severe liver disease where liver function tests have not returned to normal, undiagnosed genital bleeding, untreated endometrial hyperplasia, or known hypersensitivity to the drug components.
  • Reproductive Status: Pregnancy and lactation (breastfeeding) are absolute contraindications.

Conditional Use and Restrictions

Special caution and close supervision are required if a patient has pre-existing conditions such as uterine fibroids, endometriosis, hypertension, diabetes mellitus, or a family history of breast cancer. These conditions do not always prohibit use but require a careful assessment of risks and benefits before and during treatment.

What should I know about interactions with other medicines?

The interaction profile for Climodiene is dominated by pharmacokinetic effects related to the CYP3A4 metabolic pathway, which is responsible for the clearance of both Estradiol Valerate and Dienogest.

The combination of this medicine with strong CYP3A4 enzyme inducers—such as Rifampicin, Carbamazepine, Phenytoin, and the herbal product St. John's wort—is a contraindicated combination. Enzyme induction accelerates the metabolism of the active ingredients, which significantly decreases their systemic exposure and may lead to therapeutic failure. Conversely, co-administration with strong CYP3A4 inhibitors, such as Ketoconazole, impedes metabolism and is documented to significantly increase the plasma concentration of both hormonal components. The consumption of grapefruit or grapefruit juice may also lead to an increase in systemic exposure via intestinal enzyme inhibition.

Pharmacodynamic interactions are also officially documented. The hormonal agent may decrease the efficacy of antidiabetic drugs due to effects on carbohydrate metabolism. Additionally, the hormonal components can decrease the plasma concentration of Lamotrigine. Co-administration with Tranexamic Acid is generally not recommended. Finally, due to the critical role of the liver in drug clearance, the use of this medicine is contraindicated in patients with impaired hepatic function, as it would heighten the risk of excessive drug exposure.

Mechanism of Action

How Климодиен Works

The mechanism of action for Климодиен is driven by its two components acting within defined hormonal receptor systems and subsequent downstream regulatory pathways. The drug's influence is exerted primarily across three key mechanistic domains to achieve systemic physiological modulation.

Modulation of Key Hormonal Receptor Systems

The components, 17beta-estradiol (via estradiol valerate) and dienogest, specifically bind to and activate Estrogen Receptors (ER) and Progestin Receptors (PR), respectively. This modulation initiates systemic gene transcription changes within various hormone-dependent tissues, resulting in broad downstream physiological effects.

Progestin-Mediated Endometrial Anti-Proliferation

This critical cascade involves the dienogest component acting locally within the uterus. It triggers signals that effectively dampen estrogen-induced cell growth by down-regulating ER expression in the endometrium. This targeted interference results in secretory and differentiation changes in the uterine lining.

Influence on Metabolic and Neuro-Humoral Pathways

Beyond reproductive targets, the hormonal components influence secondary regulatory systems, including the CNS and hepatic metabolic processes. This mechanism affects pathways governing lipid synthesis and systemic protein regulation, thereby altering the functional activity of these systems.

Dosage and Administration Information

How to Use Климодиен (Climodiene): Official Administration Guidelines

Климодиен is administered as a continuous combined Hormone Replacement Therapy (HRT). The usage instructions are designed to ensure a steady daily intake of the fixed-dose combination.


Standard Dosing Regimen

Instruction Detail
Route of Administration Oral use, via a film-coated tablet.
Standard Daily Dose One tablet daily. This is a fixed-dose of Estradiol Valerate 2 mg and Dienogest 2 mg.
Dosing Schedule Continuous use (without interruption or breaks between packs).

Key Instructions for Administration

To ensure proper use, the administration should adhere to the following procedural guidelines, which are vital for maintaining the continuous hormonal exposure:

  • Timing: The tablet should preferably be taken at the same time every day.
  • Method: The tablets are to be swallowed whole with some liquid.
  • Food Intake: The medicine can be taken without regard to food.

Procedural Note for Missed Doses

If the user forgets to take a tablet, it should be taken as soon as possible. However, if the usual time is exceeded by more than 24 hours, the missed tablet must be discarded, and the next tablet should be taken at the usual time. The discarding rule is essential for maintaining the regimen's integrity.

Treatment Duration Principle

Consistent with general HRT guidelines, the treatment must adhere to the principle of using the lowest effective dose for the shortest possible duration. The need for continued therapy should be regularly re-assessed, typically at least once a year.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Climodiene

Evidence for use in Vasomotor and Psychoemotional Symptoms

The research exploring the use of this medicine for managing menopausal symptoms primarily involved Randomized Controlled Trials (RCTs), which are a common study design used for regulatory consideration. These study designs were used in research exploring how symptoms change over time in postmenopausal women with an intact uterus. Research examined study participants to track outcomes related to symptom intensity, and specifically monitored the number and severity of hot flushes and night sweats. They also applied in studies examining patient-reported experiences related to outcomes reflecting daily functioning, such as irritability, sleep disturbances, and overall mood changes.

Findings describe patterns of change observed in the studies where measured symptom scores were reported during the defined study period. The research explored short-term symptom changes in the study groups compared to groups receiving placebo. These findings contribute to understanding how patients reported their experience during the trials. While the research describes these short-term patterns, it is important to note that follow-up durations were limited to several months to one year in many of the core studies. Therefore, long-term effects are not fully established by this specific data set, and data are still emerging regarding the durability of these patterns over many years of observation.

Evidence for use in Postmenopausal Osteoporosis Risk Management

The evidence base for bone health involves both trials specific to this combination and information extrapolated from the overall class of hormone replacement therapies. Research in this area examined changes in Bone Mineral Density (BMD) at critical skeletal sites, which are outcomes related to systemic or functional imbalance.

Endometrial Protection in Combination Therapy

Because this medicine is used in women who still have their uterus, an important component of the research was conducted on the role of the progestin (Dienogest). This research was studied for its role in managing the uterine lining. Specifically, studies examined changes in endometrial morphology and its association with a protective effect.

Key Studies & References

  1. Clinical efficacy and safety of combined estradiol valerate and dienogest: a new no-bleed treatment
  2. Hormone Replacement Therapy | HRT | Menopause (MedlinePlus Overview)

Frequently Asked Questions (FAQ)

Common questions about Климодиен (FAQ)

Q: Is Климодиен the same as other hormone replacement therapies (HRT)?

A: Климодиен is a type of Hormone Replacement Therapy (HRT). Official product information states that it is a continuous combined regimen containing a fixed combination of estradiol valerate and dienogest. This specific hormone blend and continuous daily schedule make it distinct from other HRT products that may use different hormone types or cyclical dosing schedules.

Q: Can I take multivitamins or supplements while using Климодиен?

A: Official information warns of potential interactions with medicinal products that affect the CYP3A4 enzyme system and specifically mentions the herbal product St. John's wort. Specific interactions with general multivitamins are generally not listed. However, due to the potential for interactions, it is important to discuss all supplements with a healthcare professional, as not all potential interactions can be ruled out.

Q: Is it true that Климодиен helps with hot flashes?

A: Official regulatory documents indicate that Климодиен is approved for Hormone Replacement Therapy (HRT) to treat symptoms of estrogen deficiency in postmenopausal women. The authorized therapeutic indications cover the management of vasomotor symptoms, which include hot flushes and night sweats.

Q: Does Климодиен affect mood or cause mood swings?

A: The official product safety information lists depression as a possible systemic adverse effect. The hormonal components influence pathways related to mood. Any changes in mood or concerns about mental health should be discussed with a healthcare professional.

Q: Can younger women take Климодиен for reasons other than menopause?

A: The medicine is strictly indicated only for postmenopausal women to treat symptoms of estrogen deficiency. Using it for conditions other than postmenopausal estrogen deficiency is considered off-label and is not the authorized indication outlined in regulatory documents.

Q: Is a breakthrough bleed normal when first starting Климодиен?

A: The official safety information classifies irregular uterine or vaginal bleeding patterns, such as spotting or breakthrough bleeding, as a common adverse reaction in the first months. These events frequently occur during the initial adjustment period and may often resolve over time as the body adapts to the continuous combined regimen.

Q: Do I need regular blood tests while I am taking Климодиен?

A: The need for continued therapy must be regularly re-assessed by a healthcare provider, typically at least once a year. The medicine is contraindicated in patients with severe liver disease, which makes monitoring liver function tests important. A healthcare provider determines the necessity and frequency of blood work based on an individual's specific health profile.

Q: Can I switch from another HRT to Климодиен easily?

A: Regulatory documents include instructions for women switching from a sequential HRT regimen, providing specific timing for the change. Consultation with a healthcare provider is necessary to determine the appropriate timing and procedure for switching from any existing therapy.

Q: Does Климодиен affect breast tenderness?

A: Yes, the official list of adverse reactions classifies breast pain or discomfort as a common adverse effect. This potential reaction is associated with the hormonal components of the medicine.

Q: How is Климодиен different from birth control pills?

A: The official indication is for Hormone Replacement Therapy (HRT). It is important to understand that Климодиен is not a contraceptive and does not provide protection against pregnancy. The dosage and therapeutic goal differ significantly from those of oral contraceptives.

Q: Can men use Климодиен for any medical condition?

A: The product is designed and officially indicated only for use in postmenopausal women to treat symptoms of estrogen deficiency. There are no authorized indications for its use in men, as stated in the regulatory documentation.

Q: Does taking Климодиен affect future pregnancy chances (after stopping it)?

A: The medicine is explicitly contraindicated during pregnancy and lactation. Since the medicine is intended only for women who are already postmenopausal, the product information does not provide specific data on effects on fertility or pregnancy chances after stopping treatment.

Q: Does Климодиен help with sleep disturbances during menopause?

A: Clinical studies have examined patient-reported outcomes for sleep disturbances as part of assessing menopausal symptom relief. The medicine’s primary indication is for the general relief of estrogen deficiency symptoms, which may include associated sleep issues.

Q: Does Климодиен have any benefits for bone health?

A: Yes, one of the official indications is for the prevention of osteoporosis in postmenopausal women. This use is specifically authorized for women at a high risk of future fractures who are intolerant of, or unable to use, other treatments approved for osteoporosis prevention.

Q: Does Климодиен help with vaginal dryness?

A: The medicine is indicated for treating symptoms of estrogen deficiency. Relief of vulvovaginal atrophy symptoms, such as dryness, may be associated with systemic HRT, but vaginal dryness is not isolated as a primary target symptom in the official indication.

Q: Can I take Климодиен if I have a history of migraines?

A: The medicine lists headache as a common adverse reaction. The official safety precautions state that the new occurrence or worsening of migraine is an event that may necessitate the immediate discontinuation of therapy, meaning caution and clinical supervision are needed for those with a history of migraines.

Q: What is the experience like for most users who take Климодиен long-term?

A: Regulatory guidance suggests that treatment should be for the lowest effective dose for the shortest possible duration, with re-assessment at least annually. Because many core studies have limited follow-up, information regarding effects and safety over many years of continuous use is still being developed.

Q: Are there different strengths or types of Климодиен?

A: Regulatory information indicates that Климодиен is a fixed-dose combination product. It is available as a single tablet type containing 2 mg Estradiol Valerate and 2 mg Dienogest, with no mention of other authorized strengths.

Q: Can I take antibiotics while using Климодиен?

A: The product information states that certain medicinal products, particularly those that are strong CYP3A4 enzyme inducers (which may include some antibiotics), can accelerate the metabolism of the hormones. This can decrease the medicine's systemic effect, potentially leading to therapeutic failure.

Q: What is the maximum age someone can start taking Климодиен?

A: While the medicine is indicated for postmenopausal women, official safety warnings state that experience is limited in women older than 65 years. This means that starting therapy at an advanced age requires careful consideration and risk assessment by a healthcare professional.

Q: What should I do if the side effects of Климодиен bother me a lot?

A: Any significantly bothersome side effects should be discussed with a healthcare professional. Official safety guidelines advise that if a contraindication develops or if symptoms worsen, treatment may need to be stopped immediately.

Q: Does smoking affect the safety or effectiveness of Климодиен?

A: Smoking, especially heavy smoking, is a known risk factor for the serious adverse reaction of Venous Thromboembolism (VTE), which is associated with all HRT. The association between smoking and VTE means that a healthcare provider must perform a careful risk assessment related to smoking before and during the use of this medicine.

Q: Is a follow-up appointment necessary soon after starting Климодиен?

A: Regulatory guidance emphasizes that the need for continued therapy should be regularly re-assessed (typically at least once a year). This indicates that ongoing clinical supervision, including appointments to monitor progress and assess risks, is required after the initial start of treatment.

Q: Is it normal for my period to stop completely on Климодиен?

A: Климодиен is a continuous combined HRT regimen designed to be taken daily without a break. This type of continuous combined regimen is typically aimed at avoiding cyclical bleeding. While spotting may occur early on, the goal for many users is often to achieve amenorrhoea (absence of bleeding) over time.

Q: Do people notice a difference in skin or hair texture after starting Климодиен?

A: Official safety information notes the possible appearance of Chloasma (a form of skin pigmentation or darkening) as an adverse effect. It does not provide specific data on generalized changes to overall hair or skin texture.

Q: Are there any known drug interactions with common pain relievers?

A: The product information states that the hormonal components may decrease the plasma concentration of Lamotrigine, an anticonvulsant sometimes used for pain management. It is important to ensure that a healthcare professional is aware of all medicines and supplements being taken, as not all potential interactions are documented for every over-the-counter pain reliever.

How should Климодиен be stored and disposed of?

Storage and Disposal Requirements

Climodiene (estradiol valerate/dienogest) must be stored and disposed of according to the specific conditions defined in the regulatory labeling to maintain its stability and ensure public safety.


Storage Conditions

Condition Requirement
Temperature Do not store above 25 C.
Protection Store in the original package to protect the tablets from light.
Shelf-Life Has a labeled shelf-life of up to two years when stored correctly.

Disposal and Safety

Official instructions mandate that the medicine must be stored out of the sight and reach of children. Unused or expired Climodiene must not be disposed of via household waste or wastewater. Instead, the product should be returned to a pharmacist or local collection point for authorized disposal, which protects the environment from pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Климодиен found in:

A-Z Index: